Product Name | Vandetanib |
Description |
VEGFRK inhibitor |
Purity | >98% (HPLC) |
CAS No. | 443913-73-3 |
Molecular Formula | C22H24BrFN4O2 |
Molecular Weight | 475.4 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inhibitor |
Solubility | Soluble in DMSO (30 mg/ml) or EtOH (10 mg/ml) |
Source | Synthetic |
Appearance | Yellow solid |
SMILES | C1=C3C(=CC(=C1OC)OCC2CCN(CC2)C)N=CN=C3NC4=CC=C(Br)C=C4F |
InChI | InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27) |
InChIKey | UHTHHESEBZOYNR-UHFFFAOYSA-N |
Safety Phrases |
Classification: Not a hazardous substance or mixture. Safety Phrases: S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. |
Cite This Product | Vandetanib (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-483) |
Alternative Names | N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine |
Research Areas | Apoptosis, Cancer, Cancer Growth Inhibitors, Cardiovascular System, Cell Signaling, Growth Factor Receptor Inhibitors |
PubChem ID | 3081361 |
Scientific Background | Vandetanib is a selective inhibitor of VEGFR2 (Flk-1) and VEGFR3 (Flt-4), both of which are involved in angiogenesis and lymphangiogenesis. In neurodegenerative disease research, Vandetanib is used to study the role of VEGF signaling in neurovascular integrity, inflammation, and neuronal survival. Its ability to modulate vascular permeability and glial responses makes it a valuable compound for investigating vascular contributions to neurodegeneration and CNS repair. |
References | 1. Bruns C.J., et al. (2000) Clin. Cancer. Res: J. Am. Assoc. Cancer Res. 6(5): 1936–1948. |
Reviews
There are no reviews yet.